ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Aerie Announces Drug Application for Approval Accepted for Review in Europe
americanpharmaceuticalreview
October 12, 2018Aerie Pharmaceuticals reported the EMA has accepted for review the MAA for Rhokiinsa (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa in the United States and is indicated for the reduction of elevated intraocular press
Pharma Sources Insight July 2025
